Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine

NCT04798677 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Immunity
Vaccine Reaction
Influenza
Covid19
Cytokine Storm
Immunologic Deficiency Syndromes

Interventions

DIETARY_SUPPLEMENT: ABBC1 Immunoessential
DIETARY_SUPPLEMENT: Placebo

Sponsor

AB Biotek